Afatinib exerts an inhibitory effect on T cell-mediated cytotoxicity
Cancer Immunology, Immunotherapy · 2026
DOI: 10.1007/s00262-025-04279-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2026. Verfasst von Masaru Yokomura und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-Ku, Tokyo, 135-8550,…. Hauptthemen laut MEDLINE: Afatinib, Immunotherapy, Adoptive, T-Lymphocytes, Cytotoxic, Cytotoxicity, Immunologic. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: JST SPRING, Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Adoptive T cell therapy has shown significant efficacy in cancer treatment, especially in hematologic malignancies, and is increasingly being explored for solid cancers. Combining T cell therapy with conventional treatments holds promise for enhancing therapeutic effects. In this study, we conducted an in vitro inhibitor screening to evaluate the effects of various inhibitors on T cell-mediated cytotoxic activity against cancer cells. Among the candidates, we identified afatinib as an immunosuppressive agent that attenuates T cell cytotoxic activity by reducing interferon-γ (IFN-γ) secretion and suppressing T cell activation. Notably, this IFN-γ reduction was independent of T cell proliferation. RNA-seq analysis revealed that afatinib downregulated the T cell receptor (TCR) pathway signature. RT-qPCR demonstrated a dose-dependent suppression of IFNG mRNA expression in afatinib-treated T cells. Furthermore, afatinib impaired tumor rejection in an immunological memory mouse model that had been previously cured by anti-PD-L1 therapy, suggesting that afatinib may inhibit the function of effector memory T cells. Collectively, our findings highlight afatinib's potential to impair T cell effector functions, indicating that strategic consideration is essential when combining epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), including afatinib, with adoptive T cell therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-Ku, Tokyo, 135-8550, Japan.
- Department of Head and Neck Surgery, Institute of Science Tokyo, Tokyo, Japan.
- Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan.
- Department of Pathology, School of Medicine, Sapporo Medical University, Sapporo, Japan.
- Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-Ku, Tokyo, 135-8550, Japan. ryohei.katayama@jfcr.or.jp.
- Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan. ryohei.katayama@jfcr.or.jp.
Förderung
- JST SPRING
- Japan Society for the Promotion of Science
- Japan Agency for Medical Research and Development
- Nippon Foundation
Zitieren
APA
Yokomura, M., Nagano, S., Kawamoto, H., Hirohashi, Y., Torigoe, T., Asakage, T., & Katayama, R. (2026). Afatinib exerts an inhibitory effect on T cell-mediated cytotoxicity. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04279-7
Vancouver
Yokomura M, Nagano S, Kawamoto H, Hirohashi Y, Torigoe T, Asakage T, et al. Afatinib exerts an inhibitory effect on T cell-mediated cytotoxicity. Cancer Immunology, Immunotherapy. 2026. doi:10.1007/s00262-025-04279-7
BibTeX
@article{Yokomura2026,
author = {Yokomura, Masaru and Nagano, Seiji and Kawamoto, Hiroshi and Hirohashi, Yoshihiko and Torigoe, Toshihiko and Asakage, Takahiro and Katayama, Ryohei},
title = {Afatinib exerts an inhibitory effect on T cell-mediated cytotoxicity},
journal = {Cancer Immunology, Immunotherapy},
year = {2026},
doi = {10.1007/s00262-025-04279-7}
}
EUVIMED